ATP5MD

Across TCGA pan-cancer cohorts, ATP5MD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP5MD data layer compared with 21 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP5MD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP5MD expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and OV are the cancer types where ATP5MD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.877	0.615	.005	26	view →
GBM	DFS	Median	All	0.879	0.643	<.001	21	view →
OV	DFS	Tertile	All	0.922	0.441	.006	16	view →
LSCC	OS	Median	All	1.000	0.936	.009	6	view →
PDAC	DFS	Median	All	0.721	0.795	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP5MD–CCRCC (DFS)

Open the CCRCC breakdown →